PAYS Stock Overview - Paysign, Inc.

Stock Performance & Company Financials

Historical Stock Performance (Facts)

All-time high closing price: $17.95 on July 18, 2019 (Macrotrends data).
52-week range (as of mid-July 2026 reports): $3.08 – $9.30.
Recent performance: Strong YTD gains reported in 2026 (e.g., ~66% in one snapshot), with 3-year returns exceeding 300% in certain periods, outperforming broader market indices like the S&P 500 in multi-year horizons.
Beta: 0.72 (lower volatility than market).

Sources: Macrotrends, Yahoo Finance, StockAnalysis.com (via web searches July 2026).

Data Limitation: Historical performance reflects past market conditions and does not predict future results. Price data excludes dividends (none reported). 52-week ranges and returns are snapshots and may have fluctuated.

Company Financials (Facts from Filings & Reports)

Metric	2024	2025	YoY Change	Notes / Q1 2026
Revenue	$58.38M	$82.03M	+40.5%	Q1 2026: $28.04M (up ~51% YoY)
Net Income	$3.82M	$7.55M	+97.9%	Q1 2026 net income up 110% YoY
Adjusted EBITDA	$9.62M	$19.94M	+107.3%	Strong margin expansion
TTM Revenue (recent)	$91.47M
TTM Net Income	$10.40M
TTM EPS	$0.17
Employees	~226

Key Financial Highlights (Facts):

Plasma revenue: ~$45.62M in 2025 (up 4.0% YoY despite center additions offset by donation volume).
Pharma/patient affordability revenue: $33.89M in 2025 (up 167.8% YoY) due to new programs and higher claim processing.
Cardholders/programs (end-2025): ~8.4 million cardholders in ~670 programs (up from 7.3M / 600 in 2024).
Balance sheet: Strong cash position (~$20.55M reported), low debt/equity (~10.76%).

2026 Guidance (Company-Reported, Fact): Revenue $106.5M–$110.5M; Adj. EBITDA $30M–$33M; EPS $0.21–$0.26. Q2 2026 guidance also provided.

Assumptions & Uncertainties: Guidance assumes continued program launches and stable plasma dynamics; actual results may vary due to client decisions, regulatory changes, or market conditions. TTM figures are trailing twelve months as reported. Financials based on company earnings releases and 10-K/10-Q filings.

More Information: StockAnalysis Financials | Yahoo Finance | Latest 10-K (SEC)

Analyst Ratings

Consensus	# Analysts	Average Price Target	Range	Recent Actions
Strong Buy	5	$9.95 – $10.00	$8.50 – $12.75	DA Davidson: Maintain Buy $9 (May 2026); Lake Street: Raised to $11 Buy (earlier 2026)

Recent Analyst Commentary (Facts from Reports):

Multiple Buy ratings maintained or reiterated in 2026, citing strong growth in patient affordability and plasma segments.
Price targets reflect expectations of continued revenue/EBITDA expansion.

Interpretation: Analysts view PAYS favorably due to market leadership and margin expansion, but targets imply modest upside from recent trading levels.

Data Limitation: Analyst ratings and targets are opinions subject to change; not all firms cover the stock. Consensus based on available reports as of July 2026. Past ratings do not guarantee future performance.

More Information: Nasdaq Analyst Research | StockAnalysis Forecast | Yahoo Analyst Insights

Customers & Competitors

Customers (Facts)

Pharmaceutical manufacturers and patient affordability programs (major growth driver; co-pay assistance cards).
Plasma donation centers (~595 centers end-2025, market share leader ~40-50%).
Corporate clients: Rewards, incentives, disbursements, employee programs, rebates (Fortune 500, multinationals, universities, social media companies).
Government institutions and municipalities for payment solutions.
~670 active card programs serving millions of end-users (cardholders).

Source: Company 10-K filings, earnings releases, website.

Competitors (Facts & Interpretation)

Direct/niche prepaid payments: Other program managers in plasma/pharma space (specific names less prominent in public data).

Broader fintech/payments:

Brex, Tide, Mercury (corporate banking/fintech alternatives).
Payoneer, Paysafe, Repay Holdings (general payment processing).
Other prepaid/gift card providers and bank-partner ecosystems.

Interpretation: Paysign differentiates via vertical integration, proprietary technology, regulatory compliance expertise, and focus on high-volume niches like plasma and pharma (where it holds significant market share). Larger players may have scale advantages but less specialization.

Sources: Tracxn, company filings, industry analyses.

Uncertainties & Limitations: Competitor list is not exhaustive; market share estimates (~40-50% plasma) are company-reported or derived. Customer relationships are long-term but subject to contract renewals and competitive bidding. Data on exact client names often confidential.

More Information: Company Website (Solutions) | 10-K (Business/Competition Section) | Tracxn Competitor Overview

Company Overview & History

Overview (Facts): Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software solutions, and integrated payment processing primarily in the US. Markets under PaySign brand. Headquartered in Henderson, NV. ~226 employees. Sector: Technology / Software - Infrastructure.

History (Facts)

1995: Incorporated (originally as 3PEA Technologies/International).
2001/early years: Focused on co-pay assistance prepaid cards for pharma.
2011: Entered plasma donor compensation market.
2020: Name change to Paysign, Inc. to align with brand.
Recent: Shift toward patient affordability (pharma) driving growth; expanded to ~670 programs by end-2025.

Interpretation: Evolution from niche pharma player to diversified prepaid leader with scalable platform and technology moat.

Data Note: History compiled from 10-K filings and company materials. Exact early financials or all transitions may have additional details in archived documents.

More Information: paysign.com | Yahoo Profile | SEC EDGAR Filings

PAYS: Paysign, Inc. Stock Overview

Key Findings Summary